Women First to market Fournier's Esclim in US:
This article was originally published in Clinica
Women First HealthCare is to market the French company Groupe Fournier's FDA-approved oestradiol transdermal patch in the US. The Esclim patch is manufactured by Fournier's drug delivery subsidiary, Cross Site, based in Dijon, France. It is approved in 20 countries and is brand leader in France. The company claims it has the widest dosage options of any twice-weekly patch currently available in the US, where the transdermal patch market is estimated at $170 million. San Diego, California-based Women First develops and markets products aimed at menopausal women.